Among these, PTEN mutations have been reported in up to 55–80% of endometrioid endometrial tumors and their precursor lesions, while PIK3CA and ARID1A often co-occur in endometrial neoplasms, contributing to tumor progression [8,9]. This evidence concerns the gene PIK3CA and neoplasm.